New drug combo aims to tackle Hard-to-Treat myeloma
NCT ID NCT07217119
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study is testing a combination of two drugs, belantamab mafodotin and feladilimab, in 25 people with relapsed/refractory multiple myeloma who have already tried at least three other treatments. The main goal is to check the safety of the combination and find the best dose to use in future studies. Researchers will also look at how well the drugs shrink the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belantamab mafodotin and feladilimab
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong
This is a very early, small trial (25 people) focused on safety and dosing, not on proving the combination works. Side effects, including eye problems and blood issues, are possible. Many early-stage cancer drug combinations do not advance to become standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Atlanta, Georgia, 30322, United States
-
GSK Investigational Site
Madison, Wisconsin, 53792, United States
-
GSK Investigational Site
Fitzroy, Victoria, 3065, Australia
-
GSK Investigational Site
Melbourne, Victoria, 3000, Australia
-
GSK Investigational Site
Vancouver, British Columbia, V5Z1M9, Canada
-
GSK Investigational Site
Toronto, Ontario, M5G2M9, Canada
-
GSK Investigational Site
Villejuif, 94805, France
-
GSK Investigational Site
Hamburg, 22083, Germany
-
GSK Investigational Site
Utrecht, 3584CX, Netherlands
-
GSK Investigational Site
Pamplona Navarra, 31008, Spain
-
GSK Investigational Site
Stockholm, SE-141 86, Sweden